2. Academic Validation
  3. ATP6V0D1 promotes alkaliptosis by blocking STAT3-mediated lysosomal pH homeostasis

ATP6V0D1 promotes alkaliptosis by blocking STAT3-mediated lysosomal pH homeostasis

  • Cell Rep. 2023 Jan 31;42(1):111911. doi: 10.1016/j.celrep.2022.111911.
Fangquan Chen 1,  Shan Zhu 2,  Rui Kang 3,  Daolin Tang 4,  Jiao Liu 5
Affiliations

Affiliations

  • 1 DAMP Laboratory, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510150, China; Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Guangzhou Medical University, Guangzhou, Guangdong 511436, China.
  • 2 Department of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China.
  • 3 Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA.
  • 4 Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: [email protected].
  • 5 DAMP Laboratory, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510150, China; Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Guangzhou Medical University, Guangzhou, Guangdong 511436, China. Electronic address: [email protected].
PMID: 36640329 DOI: 10.1016/j.celrep.2022.111911
Abstract

Alkaliptosis, a type of regulated cell death driven by intracellular alkalization, was first described in pancreatic ductal adenocarcinoma (PDAC) cells after treatment with the opioid analgesic drug JTC801. Here, we used mass-spectrometry-based drug target identification, cellular thermal shift assay, and point mutation technologies to reveal ATP6V0D1 as a direct JTC801 target that drives alkaliptosis in human PDAC cells. Functionally, the protein stability of ATP6V0D1, when mediated by JTC801, increases the interaction between ATP6V0D1 and STAT3, resulting in increased expression and activity of STAT3 for sustaining lysosome homeostasis. Consequently, the pharmacological or genetic inhibition of STAT3 restores the sensitivity of ATP6V0D1-deficient cells to alkaliptosis in vitro or in suitable mouse models. Clinically, a high expression of ATP6V0D1 correlates with prolonged survival of patients with PDAC. Together, these results illustrate a link between ATP6V0D1 and PDAC and advance our understanding of alkaliptosis in targeted therapy.

Keywords

ATP6V0D1; CP: Cancer; STAT3; alkaliptosis; lysosome; pancreatic cancer.

Figures
Products